CSIMarket
 
Nanoviricides inc   (NNVC)
Other Ticker:  
 
 
Price: $1.1500 $-0.05 -4.167%
Day's High: $1.21 Week Perf: 1.77 %
Day's Low: $ 1.15 30 Day Perf: -3.36 %
Volume (M): 12 52 Wk High: $ 2.00
Volume (M$): $ 14 52 Wk Avg: $1.23
Open: $1.21 52 Wk Low: $1.00



 Market Capitalization (Millions $) 14
 Shares Outstanding (Millions) 12
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 0

Nanoviricides Inc
Nanoviricides Inc is a biopharmaceutical company that focuses on developing nanomedicines to combat viral infections. Their nanoviricides are designed to target specific viruses and prevent their replication inside the human body. Nanoviricides Inc utilizes nanotechnology in their drug development processes, allowing for precise targeting of viruses and minimizing off-target effects.

The company's nanoviricides are created by encasing a virus-binding ligand within a polymeric micelle that can attach to and neutralize the targeted virus. These nanoviricides can be administered orally or topically, providing a non-invasive and convenient treatment option for viral infections.

Nanoviricides Inc's approach offers several advantages over traditional antiviral drugs. The nanoviricides can potentially target a wide range of viruses, including those that mutate rapidly, and may be effective against emerging viral strains. Additionally, their nanotechnology-based platform allows for rapid development and production of new drugs, offering the potential for quicker responses to viral outbreaks.

The company has a strong focus on research and development, investing in preclinical and clinical studies to evaluate the safety and efficacy of their nanoviricides. They collaborate with academic institutions and government agencies to advance their technology and explore new applications. Nanoviricides Inc aims to address unmet medical needs by developing effective treatments for viral infections that have limited or no available therapies.


   Company Address: 1 Controls Drive Shelton 6484 CT
   Company Phone Number: 937-6137   Stock Exchange / Ticker: NYSE NNVC
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Nanoviricides Inc

Nanoviricides Inc Faces Significant Business Performance Reduction in Fiscal Period Ending Second Quarter of 2024



As Wall Street analysts and industry advisors delve into the second-quarter results of the Major Pharmaceutical Preparations industry, the focus has turned towards Nanoviricides Inc (NNVC). The organization's financial report for the period spanning October to December 2023 reveals an operating deficit of $-2.184756 million, signaling a cause for concern. This article aims to examine the context of these financial results and shed light on the potential reasons behind Nanoviricides Inc's challenging performance.
Operating Deficit Continues to Widen
Nanoviricides Inc's operating deficit for the second quarter of 2024 reflects a decline in financial stability. With a deficit of $-2.184756 million, the company's financial situation has deteriorated compared to the previous year's corresponding quarter, where the deficit stood at $-1.833994 million. Furthermore, the net deficit has widened from $-1.745 million to $-2.115 million over the past three months. The organization's struggle to generate revenue is evident, as it has not declared any during this reporting period.

Nanoviricides Inc

NNVC Makes Spectacular Debut in Q1 2024 - Unveils Groundbreaking Results Among Industry Giants



The Major Pharmaceutical Preparations industry is currently under scrutiny in the first quarter of 2024, with companies closely monitoring the financial performance of Nanoviricides Inc. With an operating deficit of $-2.031591 million, the company has failed to disclose any top-line information for the July to September 30, 2023 reporting season. This article will analyze the evolving entity's revenue generation strategies, along with its previous performance, in order to provide a comprehensive bearish outlook on Nanoviricides Inc.
Operating Deficit: An Alarming Trend
Nanoviricides Inc's inability to generate a positive operating income is a major cause for concern. In the first quarter of 2023, the company reported an operating deficit of $-1.62236 million, indicating a deteriorating financial situation. The lack of profitability raises questions regarding the effectiveness of the company's business model and its ability to provide sustainable revenue streams.

Nanoviricides Inc

Major Pharmaceutical Giant Faces Unforeseen Challenges: Operating Behavior Plummeted in Q4 2023 Earnings Season

Nanoviricides Inc, a publicly traded company, recently reported its earnings for the period from April to June 30, 2023. The company surprised its stockholders with unexpected changes in revenue during this earnings season. While the revenue remained flat at $0.00 million, investors were concerned about the operating loss of $-3.676373 million.
In evaluating the fourth quarter of 2023, it is worth noting that the operating loss increased significantly compared to the same period the previous year. The operating loss for the fourth quarter of 2022 was $-1.792783 million, which indicates a hefty increase in losses.

Nanoviricides Inc

Achieves Remarkable Financial Comeback with Reduced Losses and Improved Ranking

Nanoviricides Inc, a company in the healthcare sector of the financial market, has recorded a cumulative net loss of $-7 million during the 12 months ending in the third quarter of 2023. This resulted in a negative return on assets (ROA) of -32.19%, which is lower than the ROA of 406 other companies within the same sector. However, the company's overall ranking has improved as its ROA ranking has increased from 4212 in the second quarter of 2023 to 3115 in the third quarter of 2023.
Nanoviricides Inc has been operating at a deficit, with a loss of $-1.810741 million in the third quarter of 2023. While the company has not disclosed its revenue, it is important to note that in the third quarter of 2022, the company's operating deficit was $-1.787875 million. This indicates a slight improvement in the company's financial performance, with losses receding from $-1.793 million in the third quarter of 2022 to $-1.703 million in the third quarter of 2023.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com